Simulations Plus (SLP) witnessed a pre-market plunge of 9.84% on Wednesday, potentially driven by concerns surrounding the company's latest earnings report and an analyst downgrade.
The biopharmaceutical company reported its Q1 2025 earnings on Tuesday evening, showcasing robust growth. However, it appears that some investors were not fully satisfied with the results, leading to a selloff in the pre-market session.
Additionally, KeyBanc lowered its price target on Simulations Plus to $35 from $40, while maintaining an Overweight rating. This analyst action could have further fueled the negative sentiment surrounding the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.